Answers are grounded in this paper and cite their sources.
Immobilizing a stable prostacyclin analog on artificial surfaces significantly reduces platelet adherence, offering a potential strategy to improve the hemocompatibility of blood-contacting devices.
The adhered platelets on artificial surfaces play a crucial role in inducing thrombosis. Therefore, it is very much desirable to have surfaces which can effectively retard platelet adhesion and aggregation. Prostaglandins like PGE2, PGE1 and PGD2 possess potent antiplatelet activity, but have very short half life. A chemically stable prostacyclin analog, 10,10-difluoro-13-dehydroprostacyclin (DF2-PGI2) seems to be promising. Polyelectrolyte (PE) synthesized from natural poly cis-1,4 isoprene has also been found to possess outstanding anticoagulant and antiplatelet activity. Modification of polyetherurethane urea (PEUU) by immobilizing DF2-PGI2 and poly-electrolyte in various combinations using glow discharge technique has been attempted. Surfaces thus modified showed negligible platelet adherence. The inhibition of platelet adherence in presence of inducing agents like fibrinogen, thrombin and ADP was also remarkable. The interactions of albumin and fibrinogen with the modified surfaces were studied using 125I labelled proteins.
No takes yet. Share an insight, caveat, or question.
Joseph et al. (1987) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: